Immune Biomarkers of Chronic Lung Diseases and Lung Cancer

Dear Colleagues,

The development of personalized medicine naturally forces a change in the diagnostic approach to lung cancer and chronic lung diseases, which is possible thanks to the discovery and study of biomarkers. Immunological biomarkers can create a characteristic picture of cellular features that can be used in therapy, but also for disease identification and evaluation of micrometastases or residual disease. With the recognition of new biomarkers, in cancer therapeutics, the past 5 years have seen something of a revolution in immunologically targeted approaches to treatment, including the development of a novel therapeutic drug class of immune checkpoint-blocking antibodies.  

With this in mind, many common respiratory diseases, including pneumonia, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and lung cancer require a new diagnostic perspective. There is evidence that COPD and pulmonary fibrosis are possibly complicated by lung cancer development and importantly change the course of pulmonary malignancies. Thus, the immune background of these conditions requires special attention.  

With the number of publications on immune biomarkers rapidly increasing, now is the time to take a broad perspective of the field, putting emphasis not only on the use of biomarkers to create new therapies, but also on improving diagnostics using immunological biomarkers.

Prof. Dr. Joanna Domagala-Kulawik
Dr. Agata Raniszewska
Dr. Iwona Kwiecień
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.